Avitide, the developer of customized biopharmaceutical affinity products, has closed a Series A round of financing led by Borealis Ventures. The funding also included participation from SV Life Sciences, Polaris Venture Partners, OrbiMed Advisors and Angeli Parvi. Based in Lebanon, NH, Avitide’s technology is “designed to discover and develop affinity purification products that will improve the timeframes and economics of commercial bioprocessing.” The new funding will enable the further development of the company’s custom platform.
